eligibility_summary
Eligible: consecutive recipients of single or dual kidney transplants from ideal or marginal donors. Two cohorts: 4/1–12/31/2023 induced with one perioperative RATG infusion, reference patients before 4/1/2023 induced with seven RATG infusions (same induction/maintenance). Exclude living-donor recipients, retransplants, multiorgan transplants, PRA>30%, or positive B-cell crossmatch.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Observational matched-cohort renal transplant study comparing one vs seven perioperative infusions of RATG (Thymoglobulin) given with the same basiliximab and steroid induction and calcineurin inhibitor plus mycophenolate maintenance. Interventions and MOA: RATG is a polyclonal rabbit antithymocyte globulin (IV antibody biologic) that depletes T cells via complement-mediated lysis, opsonization, and apoptosis, and can modulate/deplete other leukocyte subsets. Basiliximab is a chimeric monoclonal antibody against IL-2 receptor alpha (CD25) that blocks IL-2–driven T-cell activation. Background drugs: calcineurin inhibitors (small molecules) inhibit calcineurin-NFAT signaling to reduce IL-2 transcription, mycophenolate (antimetabolite) inhibits IMPDH to limit lymphocyte proliferation, glucocorticoids suppress cytokine gene expression. Targets: T cells (CD2/CD3/CD25), IL-2 signaling, calcineurin-NFAT, de novo purine synthesis.